Down Syndrome (Trisomy 21): A Comprehensive Overview

Definition
Down syndrome (DS), or Trisomy 21, is a constitutional chromosomal disorder caused by the presence of an extra full or partial copy of chromosome 21. This additional genetic material disrupts typical embryonic and postnatal development, leading to a characteristic pattern of cognitive, physical, and medical features that vary widely in severity across individuals.

Three cytogenetic subtypes are clinically recognized:

• Free (non-mosaic) Trisomy 21 (~95% of cases): Results from meiotic nondisjunction—most commonly maternal meiosis I error—leading to all cells containing three copies of chromosome 21.
• Translocation Trisomy 21 (3–4% of cases): Involves the attachment of part of chromosome 21 to another acrocentric chromosome (typically 14 or 21), forming a Robertsonian translocation. While some cases are de novo, ~50% occur in offspring of carriers with balanced translocations.
• Mosaic Trisomy 21 (1–2% of cases): Arises from post-zygotic mitotic nondisjunction, resulting in a mixture of diploid and trisomic cell lines. Phenotypic expression is often milder but highly variable.

Epidemiology
The global incidence of Down syndrome is approximately 1 in 700 live births, with regional variation influenced by maternal age distribution, prenatal screening/diagnostic practices, and cultural factors.

Key Risk Factors:

• Advanced maternal age remains the strongest epidemiologic risk factor:
  • Age 20: ~1 in 1,500
  • Age 35: ~1 in 350
  • Age 40: ~1 in 100
  • Age 45: ~1 in 30
• Advanced paternal age (>40 years) is associated with a modest increase in risk for trisomy 21, though the effect size is considerably smaller than that of maternal age.
• Parental balanced Robertsonian translocations significantly elevate recurrence risk—up to 10–15% if the mother is a carrier, and 1–3% if the father is—highlighting the importance of parental karyotyping in translocation cases.

Clinical Features

Craniofacial & Musculoskeletal Characteristics:

• Brachycephaly with a flat occiput and midface hypoplasia
• Upslanting palpebral fissures with epicanthic folds
• Brushfield spots (pigmented lymphoid nodules in the iris)
• Macroglossia (enlarged tongue), often leading to protrusion and feeding difficulties
• Small, low-set ears with posteriorly rotated helices
• Single transverse palmar crease (simian crease; present in ~30–50% of individuals)
• Sandal gap deformity (widened space between the first and second toes)
• Neonatal hypotonia (central origin), persisting variably into adulthood
• Short stature and brachydactyly (short fingers), particularly fifth-digit clinodactyly

Neurological & Cognitive Profile:

• Mild to moderate intellectual disability (average IQ 50–70 in untreated populations)
• Delayed motor, speech, and language milestones
• Increased prevalence of neurodevelopmental and psychiatric conditions:
  • Autism spectrum disorder (~16–42% of individuals with DS)
  • ADHD, anxiety disorders, and obsessive-compulsive traits
  • Early-onset Alzheimer’s disease (AD): >90% develop amyloid pathology by age 40; ~50–70% exhibit dementia symptoms by age 60 due to triplication of the APP gene on chromosome 21

Associated Medical Complications

Cardiovascular (present in 40–50% of cases):

• Atrioventricular septal defect (AVSD) — the most specific and common lesion
• Ventricular septal defect (VSD)
• Atrial septal defect (ASD), particularly ostium primum type
• Patent ductus arteriosus (PDA)
• Tetralogy of Fallot (TOF)

Hematologic:

• Transient abnormal myelopoiesis (TAM): a preleukemic condition affecting ~10% of newborns with DS; typically resolves spontaneously but may cause liver fibrosis or hydrops
• Markedly elevated risk of acute megakaryoblastic leukemia (AMKL; 500-fold higher than general population) and, less commonly, B-cell acute lymphoblastic leukemia (ALL)

Endocrine:

• Congenital and acquired hypothyroidism (lifetime risk ~13–50%), necessitating lifelong surveillance
• Increased susceptibility to type 1 diabetes mellitus (~1–2% by adolescence)

ENT & Respiratory:

• Recurrent otitis media due to eustachian tube dysfunction from craniofacial anatomy and hypotonia
• Sensorineural and/or conductive hearing loss (prevalence ~50–75%)
• Obstructive sleep apnea (OSA; prevalence 30–75%), secondary to midface hypoplasia, macroglossia, and hypotonia
• Recurrent upper respiratory infections

Gastrointestinal:

• Duodenal atresia (present in ~5% of infants with DS)
• Hirschsprung disease (~2% risk)
• Celiac disease (prevalence ~5–16%, requiring serologic screening)

Orthopedic:

• Atlantoaxial instability (AAI)—horizontal ligament laxity causing excessive C1–C2 motion—in ~10–20% of individuals. While symptomatic disease is rare (<1%), universal cervical spine screening (flexion-extension radiographs) is recommended prior to anesthesia or high-impact activities
• Joint hypermobility and pes planus are common

Reproductive Health:

• Males: Near-universal azoospermia and infertility; though fertility has been reported rarely, spermatogenesis arrest is typical
• Females: Reduced but preserved fertility; pregnancy is possible, with ~50% risk of conceiving a child with DS (or translocation if familial)

Diagnosis

Prenatal Screening:

• First-trimester combined test (11⁺⁰–13⁺⁶ weeks): Nuchal translucency thickness, pregnancy-associated plasma protein-A (PAPP-A), and free β-human chorionic gonadotropin (fβ-hCG)
• Second-trimester quadruple screen (15–22 weeks): Alpha-fetoprotein (AFP), unconjugated estriol (uE3), hCG, and inhibin A
• Cell-free fetal DNA (cffDNA) testing: Highly sensitive (>99%) and specific (>99.9%) non-invasive screening for trisomy 21; recommended for high-risk pregnancies but increasingly used broadly. Note: Positive screening results must be confirmed by diagnostic testing.

Diagnostic Testing:

• Chorionic villus sampling (CVS): 10–13 weeks gestation
• Amniocentesis: ≥15 weeks gestation
• Karyotyping and/or chromosomal microarray (CMA) of cultured amniotic or chorionic tissue provides definitive diagnosis and distinguishes free, translocation, and mosaic forms

Postnatal Diagnosis:
Suspected based on characteristic physical features; confirmed via peripheral blood karyotype. CMA may supplement testing in mosaic cases to better characterize the cell line proportion.

Management & Care Coordination

There is no cure for Down syndrome; however, proactive, multidisciplinary care significantly improves health outcomes, developmental trajectories, and quality of life. Recommended coordinated interventions include:

• Cardiology: Echocardiography by 1 month of age (regardless of symptoms)
• Endocrinology: Thyroid function tests (TSH, free T4) at birth, then every 1–2 years
• Audiology & ENT: Newborn hearing screen, followed by annual audiology evaluations
• Ophthalmology: Comprehensive eye exam by 6 months of age; subsequent screenings as indicated
• Developmental pediatrics: Early intervention (EI) services beginning in infancy—speech therapy, occupational therapy, and physical therapy as needed
• Orthopedics: Cervical spine radiographs (flexion/extension views) between ages 3–5 years to assess for AAI; avoid routine athletic activities if instability is >5 mm
• Mental health & behavioral support: Screening for autism, ADHD, anxiety, and depression; access to specialized educational and psychological services
• Educational planning: Individualized Education Programs (IEPs) with inclusive, strengths-based learning strategies
• Genetic counseling: Essential for families to understand recurrence risks, reproductive options (e.g., prenatal diagnosis, preimplantation genetic testing), and implications of translocation carrier status

Life Expectancy & Long-Term Prognosis

With advances in medical care—particularly pediatric cardiac surgery and infection management—life expectancy has increased dramatically:

• Average life expectancy in 2024: ~60 years (up from ~25 years in the 1980s)
• Survival statistics:
  • 90% survive past age 10
  • ~45–50% reach age 60 or beyond

Leading causes of early mortality include congenital heart disease, respiratory infections, and complications of severe intellectual disability. As the population ages, neurodegenerative and oncologic complications become increasingly prominent.

Support & Resources

Family-centered support is integral to optimal outcomes. Parent-led organizations provide critical advocacy, education, and community connections:

• Global Down Syndrome Foundation
• National Down Syndrome Society (NDSS)
• Down Syndrome International (DSi)
• Local/regional chapters often coordinate medical home models, transition planning for adulthood, and respite care.

References

1. Bull MJ. Down syndrome. Pediatrics. 2022;149(5):e2022057565.
2. American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 818: Screening for Fetal Aneuploidy. Obstet Gynecol. 2021;137(4):e195–e213.
3. de Graaf G, et al. The demographic and survival patterns of individuals with Down syndrome in the USA: a population-based study. Genet Med. 2023;25(8):100567.
4. National Down Syndrome Society (NDSS). Health Care Guidelines for Adults with Down Syndrome, 2nd ed. 2024.
5. World Health Organization. Birth Defects Surveillance: A Manual for Integrated Data Collection and Analysis, 3rd ed. Geneva: WHO; 2023.

Note: Clinical management should follow individualized, patient-centered care plans in coordination with specialists familiar with DS-specific health guidelines (e.g., NDSS/AAFP 2024 Consensus Statement). Regular surveillance for age-related comorbidities remains essential throughout the lifespan.